Risk assessment: Who is at risk of measles in the EU/EEA?
A large epidemic of measles has affected the EU/EEA Member States in the past three years, with 44 074 cases reported to ECDC by 30 Member States between 1 January 2016 and 31 March 2019.
It is always time to test: Spring European Testing Week
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Public consultation on HPV vaccines guidance opens
This guidance covers the following areas in relation to HPV vaccination: efficacy of the nine-valent HPV vaccine, HPV vaccination in people living with HIV and HPV vaccination in males and the cost-effectiveness of extending the HPV vaccination programme to include males.
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
Programmatic management of latent tuberculosis infection in the European Union
Programmatic management of latent tuberculosis infection (LTBI) is a key component of the global tuberculosis (TB) elimination strategy. This document provides evidence-based guidance for the implementation of programmatic management of LTBI in the European Union and European Economic Area (EU/EEA).
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.